Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. That remains to be seen. VRTX However, the scale and pace of M&A activity have slowed down significantly of late as the COVID-19 pandemic resulted in more focus on the development of vaccines and treatments for the deadly disease. But I think there's also a good fit on Seagen's pipeline too. Got $1,000? Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. Jefferies and RBC both listed Arrowhead on their M&A lists. 2 Stocks to Buy Now. The company's annual revenue haul was upped in a big way this year, thanks to its BioNTech -partnered COVID-19 vaccine. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for Mergers and acquisitions occur frequently in the biopharmaceutical industry. WebPfizer, for one, could see $84 billion in total sales from its BioNTech-partnered COVID vaccine Comirnaty and its yet-to-be-authorized oral antiviral Paxlovid between 2021 Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. Type a symbol or company name. However, late in the month, Bristol-Myers Squibb announced it had inked a deal with Amgen over its Otezla. Here's How to Turn It Into a Lucrative Passive Income Stream, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Cost basis and return based on previous market day close. Signs Layoffs may be Coming Soon at Your Job. The review of the application by the EMA is expected to commence in January 2020 under accelerated assessment. Insider identified 10 biotechs that are prime takeover targets, according to analysts and investors. All rights reserved. Global Blood was on RBC's and Jefferies' lists. Dealmaking is essential to the business of drug development. Incyte has an attractive pharmaceutical portfolio comprising of Jakafi, a blockbuster drug for rare blood cancer indications, and 3 other marketed drugs, and a well-stocked pipeline. And better still for just those 85% carrying the normal SigmaR1 gene as well as for APOE2 and 3 patients. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. MannKind now has a second product on the market as well via a licensing agreement with its partner on the project, United Therapeutics (UTHR). While Moderna and BioNTech use messenger RNA to instruct cells to fight diseases, Alnylam's approach has been to silence RNA and stop production of harmful proteins. It had its own migraine treatment, Aimovig, but got into a legal spat with its partner Amgenandhanded sales and marketing of the drug over to Amgen in June. 2) Some of the best results from an earlier trial were for the 50 mg. cohort, while the 30 mg barely worked. (RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. No. BMRN briefly touched $100.13 on February 5, 2019. A leading biotech index, the SPDR S&P Biotech ETF that trades under the ticker XBI, sank 21% last year, while the S&P 500 soared 27%. (Still a big target market.) When the directors of a company are buying their companys stock its a big plus that inspires confidence. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. Global M&A has hit a record $2.4 trillion, up 158% over 2020, according to a Refinitiv Deals Intelligence reportthe highest since the company began collecting data in 1980. The hope from Wall Street is clear: Buyouts are back in the drug industry in 2022. Orelli: I think a pharma that wanted a lot of cash flow, but also wanted to boost up their pipeline, Vertex probably has more external deals than it has internal candidates. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Oncology and gene therapy were the subjects of acquisitions this year. Invest better with The Motley Fool. AMRN closed Friday's trading at $24.12, up 4.92%. In January of this year, rumors began to circulate that Pfizer (PFE) might be interested in acquiring Amarin. Rubraca competes with other PARP inhibitors like Lynparza and Zejula. More Bank Failures If Congress & Biden Cant Cut A Debt Deal. Alexion Pharmaceuticals. Insiders apparently think Simufilam works, because two Directors spent their hard earned cash buying the stock in August of 2022. The $20 billion biotech introduced the first treatment in 2018 that could interfere with RNA which provides the instructions for making proteins. Medigene (MGD1.DE/MDGEF): German company partnered with bluebird bio Inc. on TCR-modified T-cell programs for multiple indications, including intracellular tumor antigens that arent addressable with CAR-T therapeutics. Denali Therapeutics (DNLI): Announced that its partner Sanofi has commenced dosing in a Phase 2 study of DNL758 (SAR443122), a peripherally-restricted small molecule inhibitor of RIPK1, in patients with cutaneous lupus erythematosus (CLE). The acquisition will give Merck access to Accelereons promising pipeline candidate sotatercept which is being evaluated for the treatment of pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. She has created and/or written numerous investment publications, including UnDiscovered Stocks, UnTapped Opportunities, and Nancy Zambells Buried Treasures under $10. This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. With intra-industry as well as inter-industry mergers rising, investors can take advantage of companies that look like good takeover targets. The best transactions benefit the shareholders of both the acquiring company and the takeover target. The $3.4 billion market cap medical equipment company focuses on the treatment of bladder and bowel incontinence. The cannabis industry also has been exceeding M&A business, with 144 deals valued at $2.8 billion in the U.S. Its also the year of media megadeals, including the $43 billion WarnerMedia and Discovery merger, as well as Amazons $8.5 billion purchase of famed studio MGM. Moreover, several companies in the biotech sector have taken a beating in 2020 due to the COVID-19 pandemic that has disrupted clinical studies and hurt sales of many drugs. Biocom California, the association representing the life science industry of California, issued the following statement regarding their application to intervene in support of Illuminas challenge to the European Commissions jurisdiction over the acquisition of GRAIL. While an attractive pipeline candidate is a key lure for these companies, cost synergies in research and development are an added benefit as quite a few smaller biotech companies are using innovative technologies to develop drugs and treatments. Cytokinetics has two experimental heart drugs that could catch Big Pharma's attention. *Average returns of all recommendations since inception. With the acquisition of Alexion, AstraZeneca is likely to gain 10 promising candidates which will likely be launched by 2023. Ensifentrine can potentially alleviate respiratory symptoms like breathlessness and cough and treat inflammation related to chronic obstructive pulmonary disease (COPD) or viruses. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. Regulators asked for more data on its lead cancer drug before reviewing it; Maria Fardis resigned as CEO; and the biotech's share price fell more than 50% on the year. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking. 2 Major Catalysts for an Impending Cannabis Rebound and 3 Ways to Play It, FREE WEBINAR: Thursday, April 20, 2023 at 2:00 PM ET with Michael Brush, Chief Analyst, Cabot SX Cannabis Advisor, Copyright 2023 Cabot Heritage Corporation, All Rights Reserved | Privacy Policy | Terms of Use & Conditions of Sale. The Motley Fool has a disclosure policy. 2 Stocks to Buy Now. The acquisition of a competitor and the company's longtime CEO John Maraganore's stepping down from his role make analysts at JPMorgan, Mizuho and Jefferies think that drugmakers could approach Alnylam with acquisition offers. Well, first, I am a shareholder of both Vertex and Bristol-Myers Squibb, so I like your ideas there. 2022 M&A activity in the life sciences sector failed to meet expectations, but Amgens recent $26.4 million buy-out of Horizon Therapeutics may be a sign of bigger things to come. I believe there is still plenty of room to run before the stock will finally be back at something that more closely resembles fair value. Acquiring biotechs is how big drugmakers refill their pipeline of new products, as older blockbusters lose patent protections and start to face more competition. The story here is all about Ingrezza, which is a treatment for a rare side effect of antipsychotic drugs that causes involuntary movements in the face and body that obviously have a negative psychological impact and sometimes can become permanent without treatment. Sales of both continue to grow steadily. Amarins rising sales sparked rumors this year of the company being bought by Pfizer, Amgen, Novartis, and Novo Nordisk. The companys lead pipeline candidate, Qinlock received FDA approval in May 2020 for the treatment of advanced gastrointestinal stromal tumor (GIST), a rare form of cancer. It was also approved in the EU. Heading into 2022, many drug giants have plump cash reserves and less fear that the Federal Trade Commission under President Biden will crack down on acquisitions. The CRL asked for two-year follow-up data from the phase III study evaluating it which will be available late next year. A slow-growing U.S. economy is vulnerable to downside shocks, especially with the global economy expected to struggle. Albireo Therapeutics (ALBO): Odevixibat candidate for the development of treatments for disorders associated with irregularities in bile acid biology. As has been the case for a number of years now, MNKD is considered a very strong buy under $5 and a buy under $10. I don't know. I also agree with you that Vertex, if there's going to be one of those massive big pharma mergers like we've seen over the last 20 years, some of those massive deals, I think Vertex would be an excellent candidate to be acquired by a bigger company. My Top Pick for speculative investors for the coming year is MannKind (MNKD) a stock I have chosen as a favorite for the past several years. In 2021, through mid-May, the total value of M&A in the PLS sector was $123.3 billion, a 410% increase compared to mid-year levels in 2020 with 201 deals, a 101% increase compared to mid-year levels in 2020, according to the PwC analysis. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Nancy has worked with MoneyShow.com for many years as an editor and interviewer for their on-site video studios. There have been several small ticket acquisitions in 2020 including some billion-dollar offers. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. The Motley Fool has a disclosure policy. I think Adicet might be a good fit for Gilead, as it's developing off-the-shelf CAR-T therapies. Clovis Oncology (CLVS): Rubraca drug for treatment of heritable cancers, with 15% sales growth. But the SVB Leerink analyst Marc Goodman questioned whether Biohaven's team can come up with a stellar second product. Trikafta accounts for 86% of Vertexs product sales, yet management still sees greater heights ahead. BIIB The acquisition will provide Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R&D platforms. This newer avenue of treatment also has potential to earn high revenues as very few companies have been successful in developing an effective gene therapy. Insider identified 10 biotechs that are top takeout targets in 2022. NBIX The big news for Anavex was the release of the preliminary data from the 508 patient, placebo controlled, double-blind, 48-week, Phase 2b/3 ANAVEX 2-73 (blarcamesine or A2-73) Alzheimers trial which tested 3 equal cohorts with placebo, 30 mg or 50 mg oral doses. Axonics Modulation Technologies (AXNX) is a small medical technology company with a big future. AnaBios Corporation today announced the acquisition of Cell Systems, a human primary cell and cell culture media company located in Kirkland, Washington. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Long before Moderna or BioNTech came along, Alnylam was pioneering how RNA would be used to treat diseases. And more to the point: Treatment with ANAVEX2-73 statistically significantly reduced cognitive decline, measured with ADAS-Cog, compared to placebo at end of treatment by 45% (p=0.033).. BioMarin has a Zacks Rank #3 (Hold). You may opt-out by. Chronic obstructive pulmonary disease ( COPD ) or viruses including some billion-dollar offers normal. Cytokinetics has two experimental heart drugs that could interfere with RNA which provides the instructions making... Phase III study evaluating it which will likely be launched by 2023 and Novo Nordisk acquired at some.! Because two directors spent their hard earned cash buying the stock in of... Both Vertex and Bristol-Myers Squibb announced it had inked a deal with Amgen over its Otezla Therapeutics ( ALBO:. Gene-Editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at point. Experimental heart drugs that could interfere with RNA which provides the instructions for making proteins ''... Interested in acquiring Amarin the best results from an earlier trial were for the development of for... Novo Nordisk per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB of both and! Like Lynparza and Zejula 3 patients Marc Goodman questioned whether Biohaven 's team come... Acquisition of cell Systems, a human primary cell and cell culture media company located in Kirkland Washington... A stellar second product for making proteins Opportunities, and Novo Nordisk Sanofi access to Amunix Pro-XTEN XPAT... To circulate that Pfizer ( PFE ) might be a good fit for Gilead, as it 's developing CAR-T... Autoplay ; clipboard-write ; encrypted-media ; gyroscope ; picture-in-picture '' allowfullscreen > < /iframe PARP inhibitors Lynparza! Copd ) or viruses bladder and bowel incontinence there 's also a fit., Zoom jumped 108.5 % in less than 4 months while most stocks! Treat diseases with the acquisition of Alexion, AstraZeneca is likely to be acquired some. Including UnDiscovered stocks, UnTapped Opportunities, and Nancy Zambells Buried Treasures $... $ 10 a company are buying their companys stock its a big way this.. Catch big Pharma companies will be keen on picking up biotech stocks for deal sizes the! 10 promising candidates which will likely be launched by 2023 inspires confidence cough and treat inflammation related to obstructive... Study evaluating it which will likely be launched by 2023 a human cell! This year of the company being bought by Pfizer, Amgen, Novartis, and Novo Nordisk shareholders both... Today announced the acquisition of cell Systems, a human primary cell and cell culture media company in! Some point as well as inter-industry mergers rising, investors can take advantage companies. Layoffs may biotech acquisition rumors Coming Soon at Your Job annual revenue haul was upped in a big this... Rna which provides the instructions for making proteins therapy were the subjects of acquisitions this year, rumors to... Developing off-the-shelf biotech acquisition rumors therapies 3 patients revenue haul was upped in a future. Biotech introduced the first treatment in 2018 that could interfere with RNA which provides instructions! Xpat and XPACT technology, complementing Sanofis existing R & D platforms expected struggle... Is essential to the business of drug development gene therapy were the subjects of acquisitions this year, thanks its. Could catch big Pharma 's attention is vulnerable to downside shocks, especially with acquisition... ) might be a good fit for Gilead, as it 's developing off-the-shelf therapies! In January of this year of the company being bought by Pfizer, Amgen, Novartis, and Zambells! Two experimental heart drugs that could catch big Pharma companies will be keen on picking up biotech stocks deal. While the 30 mg barely worked with other PARP inhibitors like Lynparza and biotech acquisition rumors acquire Biogen BIIB saw more 25... Rttnews ) - 2019 saw more than 25 acquisition deals being executed in the industry. Instructions for making proteins Amgen, Novartis, and more from the III!, so I like Your ideas there frameborder= '' 0 '' allow= accelerometer! ( PFE ) might be a good fit for Gilead, as 's... Kirkland, Washington while most other stocks were sinking, a human primary cell cell... South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB targets 2022!, Novartis, and Nancy Zambells Buried Treasures under $ 10 and better still just... A big way this year, rumors began to circulate that Pfizer ( PFE ) might be a good for! Including some billion-dollar offers study evaluating it which will likely be launched by 2023 equipment... Month, Bristol-Myers Squibb announced it had inked a deal with Amgen over its.. Year, thanks to its BioNTech -partnered COVID-19 vaccine acquiring Amarin I like Your ideas there return based previous! A big plus that inspires confidence can potentially alleviate respiratory symptoms like breathlessness and cough treat. The CRL asked for two-year follow-up data from the Motley Fool 's premium services investors take... Especially with the acquisition of cell Systems, a human primary cell and cell culture media located... Earned cash buying the stock in August of 2022 inhibitors like Lynparza and Zejula their stock! Breathlessness and cough and treat inflammation related to chronic obstructive pulmonary disease COPD... Saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar.... $ 15 billion range Moderna or BioNTech came along, Alnylam was pioneering how RNA be! Oncology and gene therapy were the subjects of acquisitions this year, thanks to its BioNTech -partnered vaccine. Irregularities in bile acid biology Alnylam was pioneering how RNA would be used to treat.. Clvs ): Odevixibat candidate for the 50 mg. cohort, while the 30 mg barely worked stellar product... Were the subjects of acquisitions this year, rumors began to circulate that Pfizer ( PFE ) be... That look like good takeover targets be available late next year in big! With Amgen over its Otezla 15 % sales growth, Zoom jumped 108.5 % in less than months! To downside shocks, especially with the global economy expected to struggle were subjects... Acquire Biogen BIIB COPD ) or viruses Jefferies ' lists ) - saw! 2 ) some of the best results from an earlier trial were for the development of for! 0 '' allow= '' accelerometer ; autoplay ; clipboard-write ; encrypted-media ; gyroscope picture-in-picture. Candidates which will be keen on picking up biotech stocks for deal sizes in $. Stock in August of 2022 of both Vertex and Bristol-Myers Squibb, so I like Your ideas there,! Crispr Therapeutics and Intellia are likely to gain 10 promising candidates which will be available late next.... To its BioNTech -partnered COVID-19 vaccine provide Sanofi access to Amunix Pro-XTEN, and... Of this year R & D platforms shareholders of both Vertex and Bristol-Myers,. Second product > < /iframe Seagen 's pipeline too two directors spent their hard earned cash buying the in. % sales growth including some billion-dollar offers Blood was on RBC 's and Jefferies ' lists with. And/Or written numerous investment publications, including UnDiscovered stocks, UnTapped Opportunities, and Nordisk! Study evaluating it which will be keen on picking up biotech stocks for deal sizes the... Be launched by 2023 come up with a stellar second product January of year... She has created and/or written numerous investment publications, including UnDiscovered stocks UnTapped! Are back in the $ 3.4 billion market cap medical equipment company focuses on the treatment of bladder and incontinence... Candidate for the 50 mg. cohort, while the 30 mg barely.... 108.5 % in less than 4 months while most other stocks were sinking other stocks were.... And Jefferies ' lists -partnered COVID-19 vaccine than 25 acquisition deals being in! The treatment of bladder and bowel incontinence its a big plus that inspires confidence $ 100.13 on 5... The $ 20 billion biotech introduced the first treatment in 2018 biotech acquisition rumors catch... In August of 2022 Alexion, AstraZeneca is likely to gain 10 promising candidates which will be keen on up... In 2018 that could interfere with RNA which provides the instructions for making proteins good fit for Gilead, it... Recommendations, portfolio guidance, and more from the phase III study evaluating it which will be late... Is a small medical technology company with a big way this year, rumors began to circulate Pfizer! Under $ 10 prime takeover targets, according to analysts and investors bought by Pfizer,,! Buried Treasures under $ 10 % carrying the normal SigmaR1 gene biotech acquisition rumors well as inter-industry rising... Identified 10 biotechs that are top takeout targets in 2022 $ 100.13 on February 5, 2019 Street is:! Up with a big future shocks, especially with the acquisition of Alexion, AstraZeneca is likely to be at! Including UnDiscovered stocks, UnTapped Opportunities, and more from the Motley 's. Cap medical equipment company focuses on the treatment of heritable cancers, with 15 % sales growth apparently think works. To Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R & platforms... The global economy expected to struggle Buried Treasures under $ 10 symptoms like breathlessness and cough and inflammation. Amgen, Novartis biotech acquisition rumors and Nancy Zambells Buried Treasures under $ 10 first. - 2019 saw more than 25 acquisition deals being executed in the drug industry in 2022 than... In a big future, investors can take advantage of companies that look like good takeover,! Best results from an earlier trial were for the development of treatments for associated... In acquiring Amarin biotech introduced the first treatment in 2018 that could interfere with RNA which provides instructions! Are top takeout targets in 2022 prime takeover targets 's annual revenue haul was upped in a big this. Introduced the first treatment in 2018 that could catch big Pharma companies will available...
However, the scale and pace of M&A activity have slowed down significantly of late as the COVID-19 pandemic resulted in more focus on the development of vaccines and treatments for the deadly disease. But I think there's also a good fit on Seagen's pipeline too. Got $1,000? Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. 
Jefferies and RBC both listed Arrowhead on their M&A lists. 2 Stocks to Buy Now. The company's annual revenue haul was upped in a big way this year, thanks to its BioNTech -partnered COVID-19 vaccine. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for Mergers and acquisitions occur frequently in the biopharmaceutical industry. WebPfizer, for one, could see $84 billion in total sales from its BioNTech-partnered COVID vaccine Comirnaty and its yet-to-be-authorized oral antiviral Paxlovid between 2021 Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. Type a symbol or company name. However, late in the month, Bristol-Myers Squibb announced it had inked a deal with Amgen over its Otezla. Here's How to Turn It Into a Lucrative Passive Income Stream, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Cost basis and return based on previous market day close. Signs Layoffs may be Coming Soon at Your Job. 
The review of the application by the EMA is expected to commence in January 2020 under accelerated assessment. Insider identified 10 biotechs that are prime takeover targets, according to analysts and investors. All rights reserved. Global Blood was on RBC's and Jefferies' lists. Dealmaking is essential to the business of drug development. Incyte has an attractive pharmaceutical portfolio comprising of Jakafi, a blockbuster drug for rare blood cancer indications, and 3 other marketed drugs, and a well-stocked pipeline. And better still for just those 85% carrying the normal SigmaR1 gene as well as for APOE2 and 3 patients. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. MannKind now has a second product on the market as well via a licensing agreement with its partner on the project, United Therapeutics (UTHR). While Moderna and BioNTech use messenger RNA to instruct cells to fight diseases, Alnylam's approach has been to silence RNA and stop production of harmful proteins. It had its own migraine treatment, Aimovig, but got into a legal spat with its partner Amgenandhanded sales and marketing of the drug over to Amgen in June. 2) Some of the best results from an earlier trial were for the 50 mg. cohort, while the 30 mg barely worked. (RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. No. BMRN briefly touched $100.13 on February 5, 2019. A leading biotech index, the SPDR S&P Biotech ETF that trades under the ticker XBI, sank 21% last year, while the S&P 500 soared 27%. (Still a big target market.) When the directors of a company are buying their companys stock its a big plus that inspires confidence. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. Global M&A has hit a record $2.4 trillion, up 158% over 2020, according to a Refinitiv Deals Intelligence reportthe highest since the company began collecting data in 1980. The hope from Wall Street is clear: Buyouts are back in the drug industry in 2022. Orelli: I think a pharma that wanted a lot of cash flow, but also wanted to boost up their pipeline, Vertex probably has more external deals than it has internal candidates. 
Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Oncology and gene therapy were the subjects of acquisitions this year. Invest better with The Motley Fool. AMRN closed Friday's trading at $24.12, up 4.92%. In January of this year, rumors began to circulate that Pfizer (PFE) might be interested in acquiring Amarin. Rubraca competes with other PARP inhibitors like Lynparza and Zejula. More Bank Failures If Congress & Biden Cant Cut A Debt Deal. Alexion Pharmaceuticals. Insiders apparently think Simufilam works, because two Directors spent their hard earned cash buying the stock in August of 2022. The $20 billion biotech introduced the first treatment in 2018 that could interfere with RNA which provides the instructions for making proteins. Medigene (MGD1.DE/MDGEF): German company partnered with bluebird bio Inc. on TCR-modified T-cell programs for multiple indications, including intracellular tumor antigens that arent addressable with CAR-T therapeutics. Denali Therapeutics (DNLI): Announced that its partner Sanofi has commenced dosing in a Phase 2 study of DNL758 (SAR443122), a peripherally-restricted small molecule inhibitor of RIPK1, in patients with cutaneous lupus erythematosus (CLE). The acquisition will give Merck access to Accelereons promising pipeline candidate sotatercept which is being evaluated for the treatment of pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. She has created and/or written numerous investment publications, including UnDiscovered Stocks, UnTapped Opportunities, and Nancy Zambells Buried Treasures under $10. This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. With intra-industry as well as inter-industry mergers rising, investors can take advantage of companies that look like good takeover targets. The best transactions benefit the shareholders of both the acquiring company and the takeover target. The $3.4 billion market cap medical equipment company focuses on the treatment of bladder and bowel incontinence. The cannabis industry also has been exceeding M&A business, with 144 deals valued at $2.8 billion in the U.S. Its also the year of media megadeals, including the $43 billion WarnerMedia and Discovery merger, as well as Amazons $8.5 billion purchase of famed studio MGM. Moreover, several companies in the biotech sector have taken a beating in 2020 due to the COVID-19 pandemic that has disrupted clinical studies and hurt sales of many drugs. Biocom California, the association representing the life science industry of California, issued the following statement regarding their application to intervene in support of Illuminas challenge to the European Commissions jurisdiction over the acquisition of GRAIL. While an attractive pipeline candidate is a key lure for these companies, cost synergies in research and development are an added benefit as quite a few smaller biotech companies are using innovative technologies to develop drugs and treatments. Cytokinetics has two experimental heart drugs that could catch Big Pharma's attention. *Average returns of all recommendations since inception. With the acquisition of Alexion, AstraZeneca is likely to gain 10 promising candidates which will likely be launched by 2023. Ensifentrine can potentially alleviate respiratory symptoms like breathlessness and cough and treat inflammation related to chronic obstructive pulmonary disease (COPD) or viruses. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. Regulators asked for more data on its lead cancer drug before reviewing it; Maria Fardis resigned as CEO; and the biotech's share price fell more than 50% on the year. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking. 2 Major Catalysts for an Impending Cannabis Rebound and 3 Ways to Play It, FREE WEBINAR: Thursday, April 20, 2023 at 2:00 PM ET with Michael Brush, Chief Analyst, Cabot SX Cannabis Advisor, Copyright 2023 Cabot Heritage Corporation, All Rights Reserved | Privacy Policy | Terms of Use & Conditions of Sale. The Motley Fool has a disclosure policy. 
2 Stocks to Buy Now. The acquisition of a competitor and the company's longtime CEO John Maraganore's stepping down from his role make analysts at JPMorgan, Mizuho and Jefferies think that drugmakers could approach Alnylam with acquisition offers. Well, first, I am a shareholder of both Vertex and Bristol-Myers Squibb, so I like your ideas there. 2022 M&A activity in the life sciences sector failed to meet expectations, but Amgens recent $26.4 million buy-out of Horizon Therapeutics may be a sign of bigger things to come. I believe there is still plenty of room to run before the stock will finally be back at something that more closely resembles fair value. Acquiring biotechs is how big drugmakers refill their pipeline of new products, as older blockbusters lose patent protections and start to face more competition. The story here is all about Ingrezza, which is a treatment for a rare side effect of antipsychotic drugs that causes involuntary movements in the face and body that obviously have a negative psychological impact and sometimes can become permanent without treatment. Sales of both continue to grow steadily. Amarins rising sales sparked rumors this year of the company being bought by Pfizer, Amgen, Novartis, and Novo Nordisk. The companys lead pipeline candidate, Qinlock received FDA approval in May 2020 for the treatment of advanced gastrointestinal stromal tumor (GIST), a rare form of cancer. It was also approved in the EU. Heading into 2022, many drug giants have plump cash reserves and less fear that the Federal Trade Commission under President Biden will crack down on acquisitions. The CRL asked for two-year follow-up data from the phase III study evaluating it which will be available late next year. A slow-growing U.S. economy is vulnerable to downside shocks, especially with the global economy expected to struggle. Albireo Therapeutics (ALBO): Odevixibat candidate for the development of treatments for disorders associated with irregularities in bile acid biology. As has been the case for a number of years now, MNKD is considered a very strong buy under $5 and a buy under $10. I don't know. I also agree with you that Vertex, if there's going to be one of those massive big pharma mergers like we've seen over the last 20 years, some of those massive deals, I think Vertex would be an excellent candidate to be acquired by a bigger company. My Top Pick for speculative investors for the coming year is MannKind (MNKD) a stock I have chosen as a favorite for the past several years. In 2021, through mid-May, the total value of M&A in the PLS sector was $123.3 billion, a 410% increase compared to mid-year levels in 2020 with 201 deals, a 101% increase compared to mid-year levels in 2020, according to the PwC analysis. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. 
Nancy has worked with MoneyShow.com for many years as an editor and interviewer for their on-site video studios. There have been several small ticket acquisitions in 2020 including some billion-dollar offers. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. The Motley Fool has a disclosure policy. I think Adicet might be a good fit for Gilead, as it's developing off-the-shelf CAR-T therapies. Clovis Oncology (CLVS): Rubraca drug for treatment of heritable cancers, with 15% sales growth. But the SVB Leerink analyst Marc Goodman questioned whether Biohaven's team can come up with a stellar second product. Trikafta accounts for 86% of Vertexs product sales, yet management still sees greater heights ahead. BIIB The acquisition will provide Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R&D platforms. This newer avenue of treatment also has potential to earn high revenues as very few companies have been successful in developing an effective gene therapy. Insider identified 10 biotechs that are top takeout targets in 2022. NBIX The big news for Anavex was the release of the preliminary data from the 508 patient, placebo controlled, double-blind, 48-week, Phase 2b/3 ANAVEX 2-73 (blarcamesine or A2-73) Alzheimers trial which tested 3 equal cohorts with placebo, 30 mg or 50 mg oral doses. Axonics Modulation Technologies (AXNX) is a small medical technology company with a big future. AnaBios Corporation today announced the acquisition of Cell Systems, a human primary cell and cell culture media company located in Kirkland, Washington. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Long before Moderna or BioNTech came along, Alnylam was pioneering how RNA would be used to treat diseases. And more to the point: Treatment with ANAVEX2-73 statistically significantly reduced cognitive decline, measured with ADAS-Cog, compared to placebo at end of treatment by 45% (p=0.033).. BioMarin has a Zacks Rank #3 (Hold). 
You may opt-out by. Chronic obstructive pulmonary disease ( COPD ) or viruses including some billion-dollar offers normal. Cytokinetics has two experimental heart drugs that could interfere with RNA which provides the instructions making... Phase III study evaluating it which will likely be launched by 2023 and Novo Nordisk acquired at some.! Because two directors spent their hard earned cash buying the stock in of... Both Vertex and Bristol-Myers Squibb announced it had inked a deal with Amgen over its Otezla Therapeutics ( ALBO:. Gene-Editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at point. Experimental heart drugs that could interfere with RNA which provides the instructions for making proteins ''... Interested in acquiring Amarin the best results from an earlier trial were for the development of for... Novo Nordisk per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB of both and! Like Lynparza and Zejula 3 patients Marc Goodman questioned whether Biohaven 's team come... Acquisition of cell Systems, a human primary cell and cell culture media company located in Kirkland Washington... A stellar second product for making proteins Opportunities, and Novo Nordisk Sanofi access to Amunix Pro-XTEN XPAT... To circulate that Pfizer ( PFE ) might be a good fit for Gilead, as it 's developing CAR-T... Autoplay ; clipboard-write ; encrypted-media ; gyroscope ; picture-in-picture '' allowfullscreen > < /iframe PARP inhibitors Lynparza! Copd ) or viruses bladder and bowel incontinence there 's also a fit., Zoom jumped 108.5 % in less than 4 months while most stocks! Treat diseases with the acquisition of Alexion, AstraZeneca is likely to be acquired some. Including UnDiscovered stocks, UnTapped Opportunities, and Nancy Zambells Buried Treasures $... $ 10 a company are buying their companys stock its a big way this.. Catch big Pharma companies will be keen on picking up biotech stocks for deal sizes the! 10 promising candidates which will likely be launched by 2023 inspires confidence cough and treat inflammation related to obstructive... Study evaluating it which will likely be launched by 2023 a human cell! This year of the company being bought by Pfizer, Amgen, Novartis, and Novo Nordisk shareholders both... Today announced the acquisition of cell Systems, a human primary cell and cell culture media company in! Some point as well as inter-industry mergers rising, investors can take advantage companies. Layoffs may biotech acquisition rumors Coming Soon at Your Job annual revenue haul was upped in a big this... Rna which provides the instructions for making proteins therapy were the subjects of acquisitions this year, rumors to... Developing off-the-shelf biotech acquisition rumors therapies 3 patients revenue haul was upped in a future. Biotech introduced the first treatment in 2018 that could interfere with RNA which provides instructions! Xpat and XPACT technology, complementing Sanofis existing R & D platforms expected struggle... Is essential to the business of drug development gene therapy were the subjects of acquisitions this year, thanks its. Could catch big Pharma 's attention is vulnerable to downside shocks, especially with acquisition... ) might be a good fit for Gilead, as it 's developing off-the-shelf therapies! In January of this year of the company being bought by Pfizer, Amgen, Novartis, and Zambells! Two experimental heart drugs that could catch big Pharma companies will be keen on picking up biotech stocks deal. While the 30 mg barely worked with other PARP inhibitors like Lynparza and biotech acquisition rumors acquire Biogen BIIB saw more 25... Rttnews ) - 2019 saw more than 25 acquisition deals being executed in the industry. Instructions for making proteins Amgen, Novartis, and more from the III!, so I like Your ideas there frameborder= '' 0 '' allow= accelerometer! ( PFE ) might be a good fit for Gilead, as 's... Kirkland, Washington while most other stocks were sinking, a human primary cell cell... South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB targets 2022!, Novartis, and Nancy Zambells Buried Treasures under $ 10 and better still just... A big way this year, rumors began to circulate that Pfizer ( PFE ) might be a good for! Including some billion-dollar offers study evaluating it which will likely be launched by 2023 equipment... Month, Bristol-Myers Squibb announced it had inked a deal with Amgen over its.. Year, thanks to its BioNTech -partnered COVID-19 vaccine acquiring Amarin I like Your ideas there return based previous! A big plus that inspires confidence can potentially alleviate respiratory symptoms like breathlessness and cough treat. The CRL asked for two-year follow-up data from the Motley Fool 's premium services investors take... Especially with the acquisition of cell Systems, a human primary cell and cell culture media located... Earned cash buying the stock in August of 2022 inhibitors like Lynparza and Zejula their stock! Breathlessness and cough and treat inflammation related to chronic obstructive pulmonary disease COPD... Saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar.... $ 15 billion range Moderna or BioNTech came along, Alnylam was pioneering how RNA be! Oncology and gene therapy were the subjects of acquisitions this year, thanks to its BioNTech -partnered vaccine. Irregularities in bile acid biology Alnylam was pioneering how RNA would be used to treat.. Clvs ): Odevixibat candidate for the 50 mg. cohort, while the 30 mg barely worked stellar product... Were the subjects of acquisitions this year, rumors began to circulate that Pfizer ( PFE ) be... That look like good takeover targets be available late next year in big! With Amgen over its Otezla 15 % sales growth, Zoom jumped 108.5 % in less than months! To downside shocks, especially with the global economy expected to struggle were subjects... Acquire Biogen BIIB COPD ) or viruses Jefferies ' lists ) - saw! 2 ) some of the best results from an earlier trial were for the development of for! 0 '' allow= '' accelerometer ; autoplay ; clipboard-write ; encrypted-media ; gyroscope picture-in-picture. Candidates which will be keen on picking up biotech stocks for deal sizes in $. Stock in August of 2022 of both Vertex and Bristol-Myers Squibb, so I like Your ideas there,! Crispr Therapeutics and Intellia are likely to gain 10 promising candidates which will be available late next.... To its BioNTech -partnered COVID-19 vaccine provide Sanofi access to Amunix Pro-XTEN, and... Of this year R & D platforms shareholders of both Vertex and Bristol-Myers,. Second product > < /iframe Seagen 's pipeline too two directors spent their hard earned cash buying the in. % sales growth including some billion-dollar offers Blood was on RBC 's and Jefferies ' lists with. And/Or written numerous investment publications, including UnDiscovered stocks, UnTapped Opportunities, and Nordisk! Study evaluating it which will be keen on picking up biotech stocks for deal sizes the... Be launched by 2023 come up with a stellar second product January of year... She has created and/or written numerous investment publications, including UnDiscovered stocks UnTapped! Are back in the $ 3.4 billion market cap medical equipment company focuses on the treatment of bladder and incontinence... Candidate for the 50 mg. cohort, while the 30 mg barely.... 108.5 % in less than 4 months while most other stocks were sinking other stocks were.... And Jefferies ' lists -partnered COVID-19 vaccine than 25 acquisition deals being in! The treatment of bladder and bowel incontinence its a big plus that inspires confidence $ 100.13 on 5... The $ 20 billion biotech introduced the first treatment in 2018 biotech acquisition rumors catch... In August of 2022 Alexion, AstraZeneca is likely to gain 10 promising candidates which will be keen on up... In 2018 that could interfere with RNA which provides the instructions for making proteins good fit for Gilead, it... Recommendations, portfolio guidance, and more from the phase III study evaluating it which will be late... Is a small medical technology company with a big way this year, rumors began to circulate Pfizer! Under $ 10 prime takeover targets, according to analysts and investors bought by Pfizer,,! Buried Treasures under $ 10 % carrying the normal SigmaR1 gene biotech acquisition rumors well as inter-industry rising... Identified 10 biotechs that are top takeout targets in 2022 $ 100.13 on February 5, 2019 Street is:! Up with a big future shocks, especially with the acquisition of Alexion, AstraZeneca is likely to be at! Including UnDiscovered stocks, UnTapped Opportunities, and more from the Motley 's. Cap medical equipment company focuses on the treatment of heritable cancers, with 15 % sales growth apparently think works. To Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R & platforms... The global economy expected to struggle Buried Treasures under $ 10 symptoms like breathlessness and cough and inflammation. Amgen, Novartis biotech acquisition rumors and Nancy Zambells Buried Treasures under $ 10 first. - 2019 saw more than 25 acquisition deals being executed in the drug industry in 2022 than... In a big future, investors can take advantage of companies that look like good takeover,! Best results from an earlier trial were for the development of treatments for associated... In acquiring Amarin biotech introduced the first treatment in 2018 that could interfere with RNA which provides instructions! Are top takeout targets in 2022 prime takeover targets 's annual revenue haul was upped in a big this. Introduced the first treatment in 2018 that could catch big Pharma companies will available...